Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases.
Resche-Rigon M, Pirracchio R, Robin M, De Latour RP, Sibon D, Ades L, Ribaud P, Fermand JP, Thieblemont C, Socié G, Chevret S. Resche-Rigon M, et al. Among authors: sibon d. BMC Blood Disord. 2012 Aug 16;12:10. doi: 10.1186/1471-2326-12-10. BMC Blood Disord. 2012. PMID: 22898556 Free PMC article.
ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study.
Sibon D, Bisig B, Bonnet C, Poullot E, Bachy E, Cavalieri D, Fataccioli V, Bregnard C, Drieux F, Bruneau J, Lemonnier F, Dupuy A, Bossard C, Parrens M, Bouabdallah K, Ketterer N, Berthod G, Cairoli A, Damaj G, Tournilhac O, Jais JP, Gaulard P, De Leval L. Sibon D, et al. Haematologica. 2023 Jun 1;108(6):1590-1603. doi: 10.3324/haematol.2022.281442. Haematologica. 2023. PMID: 36453105 Free PMC article.
Aflibercept-mediated early angiogenic changes in aggressive B-cell lymphoma.
Romero M, Brière J, de Bazelaire C, Lebœuf C, Wang L, Ratajczak P, Sibon D, de Kerviler E, Thieblemont C, Janin A. Romero M, et al. Among authors: sibon d. Cancer Chemother Pharmacol. 2011 Nov;68(5):1135-43. doi: 10.1007/s00280-011-1589-9. Epub 2011 Mar 5. Cancer Chemother Pharmacol. 2011. PMID: 21380563
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
Sibon D, Ertault M, Al Nawakil C, de Bazelaire C, Franchi P, Brière J, de Kerviler E, Beranger N, Thieblemont C, Brice P. Sibon D, et al. Br J Haematol. 2011 Apr;153(2):191-8. doi: 10.1111/j.1365-2141.2011.08594.x. Epub 2011 Mar 8. Br J Haematol. 2011. PMID: 21385169 Free article. Clinical Trial.
Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, Sibon D, Thieblemont C, Dupuis J, Terrier B, Feray C, Tilly H, Pol S, Leblond V, Settegrana C, Rabiega P, Barthe Y, Hendel-Chavez H, Nguyen-Khac F, Merle-Béral H, Berger F, Molina T, Charlotte F, Carrat F, Davi F, Hermine O, Besson C; ANRS HC-13 Lympho-C Study Group. Michot JM, et al. Among authors: sibon d. Am J Hematol. 2015 Mar;90(3):197-203. doi: 10.1002/ajh.23889. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25417909 Free article. Clinical Trial.
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.
Sibon D, Morschhauser F, Resche-Rigon M, Ghez D, Dupuis J, Marçais A, Deau-Fischer B, Bouabdallah R, Sebban C, Salles G, Brice P. Sibon D, et al. Haematologica. 2016 Apr;101(4):474-81. doi: 10.3324/haematol.2015.136408. Epub 2015 Dec 31. Haematologica. 2016. PMID: 26721893 Free PMC article. Clinical Trial.
In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas.
Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, Davi F, Settegrana C, Berger F, Alric L, Cacoub P, Terrier B, Suarez F, Sibon D, Dupuis J, Feray C, Tilly H, Pol S, Deau Fischer B, Roulland S, Thieblemont C, Leblond V, Carrat F, Hermine O, Besson C; national ANRS HC13 LymphoC study. Canioni D, et al. Among authors: sibon d. PLoS One. 2016 Jun 3;11(6):e0156384. doi: 10.1371/journal.pone.0156384. eCollection 2016. PLoS One. 2016. PMID: 27257992 Free PMC article.
Brentuximab vedotin as a bridge to allogeneic stem-cell transplantation for refractory or relapsing patients with CD30 positive anaplastic or T-cell non-Hodgkin lymphomas: a study on behalf of the SFGM-TC.
Garciaz S, Loschi M, De Masson A, Biard L, Mercier M, Tomowiak C, Delage J, Labussiere-Wallet H, Sibon D, Cassuto O, Borel C, Cornillon J, Nimubona S, Charbonnier A, Brice P, Socié G, Bouabdallah R, de Latour RP, de Fontbrune FS. Garciaz S, et al. Among authors: sibon d. Leuk Lymphoma. 2019 Nov;60(11):2802-2805. doi: 10.1080/10428194.2019.1599112. Epub 2019 Apr 24. Leuk Lymphoma. 2019. PMID: 31014144 No abstract available.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Le Gouill S, Ghesquières H, Oberic L, Morschhauser F, Tilly H, Ribrag V, Lamy T, Thieblemont C, Maisonneuve H, Gressin R, Bouhabdallah K, Haioun C, Damaj G, Fornecker L, Bouhabdallah R, Feugier P, Sibon D, Cartron G, Bonnet C, André M, Chartier L, Ruminy P, Kraeber-Bodéré F, Bodet-Milin C, Berriolo-Riedinger A, Brière J, Jais JP, Molina TJ, Itti E, Casasnovas RO. Le Gouill S, et al. Among authors: sibon d. Blood. 2021 Apr 29;137(17):2307-2320. doi: 10.1182/blood.2020008750. Blood. 2021. PMID: 33211799 Free article.
85 results